Medical/Pharmaceuticals
First-ever Shingles Awareness Week highlights misconceptions about the risk of developing shingles among older adults, and the need for more education
* GSK has launched the inaugural Shingles Awareness Week to educate the general public about shingles in collaboration with the International Federation on Ageing * Over 90% of adults, above the age of 50, already carry the virus that causes shingles, and 1 in 3 adults will develop shingles i...
2022-02-28 10:00
2117
ALPS PHARMA LAUNCHES A NEW QUERCETIN DELIVERY COMPOSITION
HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company pioneering phytochemicals in medicine and food,today announced the launch of a water-soluble Quercetin delivery composition, Eubioflavonoid® derived from Sopho...
2022-02-28 09:19
2027
ALPS PHARMA LAUNCHES A NEW WATER-SOLUBLE ISOQUERCETIN COMPOSITION WITH HIGHER ABSORPTION RATE
HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio®Isoquercetin,today. Eubio®Isoqu...
2022-02-28 09:16
2133
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis
HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (A...
2022-02-28 08:00
4263
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...
2022-02-27 18:30
6894
Jean-Luc Herbeaux to become Hovione CEO
LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that
the Board of Directors and the shareholders have approved the appointment of
Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April
2022.
2022-02-25 22:00
3713
Fosun Foundation's First Batch of 250,000 Sets of COVID-19 Rapid Antigen Test Kits Arrives in Hong Kong
HONG KONG, Feb. 25, 2022 /PRNewswire/ -- In an effort to support Hong Kong's fight against the severe fifth wave of COVID-19 epidemic, Fosun Foundation announced last week the donation ofHK$10 million anti-epidemic materials, including COVID-19 rapid antigen test kits and face masks toHong Kong. ...
2022-02-25 12:33
5695
Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
NEW YORK and HONG KONG, Feb. 25, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in a Phase I clinical trial evaluating ISM001-055, the first anti-fibroti...
2022-02-25 00:00
5700
C2i Genomics Applauded by Frost & Sullivan for Enabling Real-time Cancer Monitoring Using Genomic Data with Its C2intelligence Platform
The C2intelligence Platform enables custom, cost-effective, efficient, automatic, and globally accessible cancer data management and real-time monitoring. SAN ANTONIO, Feb. 24, 2022 /PRNewswire/ -- Based on a recent industry analysis,Frost & Sullivan recognizes C2i Genomics with the 2022 North A...
2022-02-24 21:00
3435
SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies
The SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research decisions BOSTON and LAUSANNE, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine,...
2022-02-24 20:57
2840
Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era
SEOUL, South Korea, Feb. 24, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay. This new assay is optimized for the 'living with COVID-19' era, where mass, swift and ...
2022-02-24 20:00
2944
India's Largest Digital Healthcare Company MediBuddy Raises USD 125 Million in Series C Funding
Largest funding round in the Digital Healthcare services space BANGALORE, India, Feb. 24, 2022 /PRNewswire/ -- MediBuddy, India's largest end-to-end digital healthcare platform, has raisedUSD 125 million in Series C funding fromQuadria Capital and Lightrock India along with participation from ex...
2022-02-24 18:57
3688
Dr Ivan Puah Reveals That Using Calcium Hydroxyapatite Injection (Radiesse(R)) Post Liposuction Can Improve Skin Laxity Significantly
SINGAPORE, Feb. 24, 2022 /PRNewswire/ -- Calcium hydroxyapatite, also known as CaHA, in Radiesse®️ is the first and only FDA-approved filler available that provides both immediate and natural-looking results. Besides reversing volume loss in the face and hands, Radiesse®️ also stimulates colla...
2022-02-24 18:54
3833
Elekta: Interim report, May-January 2021/22
STOCKHOLM, Feb. 24, 2022 /PRNewswire/ -- The demand for Elekta's solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta's strongest order backlog ever. However, the global supply chain challenges remained, and revenue...
2022-02-24 17:13
4036
CSR Committee: PQE Group establishes internal department to enhance charitable and volunteering projects' governance
FLORENCE, Italy, Feb. 24, 2022 /PRNewswire/ -- For more than 4 years, PQE Group
2022-02-24 17:00
2574
Connected pen injector add-on designed by SHL Medical wins 2021 Good Design Award
ZUG, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SHL Medical and Innovation Zed is pleased to share the news that Innovation Zed's injection time-tracker connected device, the InsulCheck CONNECT, a device that was designed by SHL Medical, has been selected as a winner of the 2021 Good Design Award...
2022-02-24 15:00
3237
Sino Group and Ng Teng Fong Charitable Foundation Partner with HKCSS and Social Welfare Department to Distribute 500 Belun(R) remoVital Remote Monitoring Systems to Care Homes
HONG KONG, Feb. 24, 2022 /PRNewswire/ -- Sino Group and the Ng Teng Fong Charitable Foundation, its philanthropic arm, are partnering with the Hong Kong Council of Social Service (HKCSS) and the Social Welfare Department to distribute 500 Belun® remoVital remote monitoring systems to residential ...
2022-02-24 14:26
4312
Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research
SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announcedClinical Cancer Research, a journal of the American Association for Cancer Research (AACR), published the data from a phase I clinical study of the company's proprietary HER2 bispecific antibody KN026 fo...
2022-02-24 09:41
3476
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
SAN FRANCISCO and SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-02-24 08:00
4697
Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II ("LAD-II"). Orpha Labs AG is w...
2022-02-23 21:27
3651
Week's Top Stories
Most Reposted
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 291 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 278 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 274 media titles]
2026-09-25 14:45
Most Read
The Sanya EDITION Presents an Island Celebration Experience for Mid-Autumn Festival and China National Day Golden Week
2026-09-19 09:00
7370
iScreen Expands iOS 27 Customization With New Extra-Large Widget Experiences, iPhone Duo Theme Support and AI-Powered Home Screen Design
2026-09-19 06:00
7339
